Product Description
Novo Nordisk was developing nn-9925, an oral GLP-1 Agonist for Diabetes Mellitus, Type 2
Mechanisms of Action: GLP-1 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novo Nordisk
Company Location: BAGSVAERD DENMARK G7 00000
Company CEO: Lars Fruergaard Jorgensen
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NN9925-3779 | P1 |
Completed |
Type 2 Diabetes |
2010-09-16 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|